KORU Medical Systems, Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

This summary offers a clear, investor-focused overview of KORU Medical Systems, Inc.'s performance and strategic direction, based on its annual report for the fiscal year ended December 31, 2025. KORU Medical Systems, Inc. (Nasdaq: KRMD) operates as a "non-accelerated filer" and "smaller reporting company," meaning it has fewer reporting requirements than larger public companies.

Business Overview: Empowering Home Infusion

KORU Medical Systems is a medical technology company dedicated to improving the lives of patients with chronic diseases through innovative home and specialty infusion solutions. KORU primarily develops, manufactures, and commercializes medical devices and consumables for subcutaneous (under the skin) drug delivery. This focus particularly benefits therapies like Subcutaneous Immunoglobulin (SCIg) for patients with primary immunodeficiencies. Its flagship product line, the FREEDOM Infusion System, provides a comfortable and convenient infusion experience outside of clinical settings.

Financial Performance: A Mixed Year with Strategic Investments

KORU experienced a mixed financial year in 2025, characterized by strategic investments and ongoing market adjustments.

• Revenue: Total revenue for fiscal year 2025 reached $62.5 million, a 3% increase from $60.7 million in fiscal year 2024. Increased adoption of infusion sets and accessories primarily drove this modest growth, partially offset by a slight decline in pump sales.
• Gross Profit: Gross profit stood at $38.0 million, with a gross margin of 60.8%, consistent with the prior year.
• Net Income/Loss: The company reported a net loss of $8.2 million, or ($0.25) per diluted share, compared to a net loss of $6.5 million, or ($0.20) per diluted share, in 2024. This increased loss reflects higher operating expenses from research and development for its next-generation pump system and expanded sales and marketing efforts.
• Operating Expenses: Research and Development (R&D) expenses increased by 15% to $12.5 million, reflecting significant investment in KORU's new product pipeline. Selling, General, and Administrative (SG&A) expenses rose by 8% to $33.7 million, driven by commercial expansion and inflationary pressures.

Management's Discussion and Analysis (MD&A) Highlights

Management discusses KORU's financial condition and operations in this section, highlighting key operational achievements, challenges, and strategic initiatives.

Operational Highlights & Challenges: Major Wins:

• Next-Generation Pump Development: KORU significantly advanced its next-generation pump and consumable system, completing the design freeze (finalizing the design before manufacturing) and beginning verification and validation testing. The company expects to submit a 510(k) premarket notification to the FDA in Q3 2026, a key step for medical device approval.
• Market Share Expansion: KORU successfully expanded its market share in key U.S. regions for SCIg home infusion, driven by targeted physician education and patient support programs.
• Strategic Partnerships: KORU secured a new supply agreement with a leading biopharmaceutical company to co-promote its infusion systems alongside a newly approved SCIg therapy. This partnership is expected to ramp up in late 2026.
• Operational Efficiency: KORU implemented new manufacturing automation, reducing per-unit production costs for certain high-volume consumables by 5%.

Key Challenges:

• Supply Chain Volatility: Ongoing global supply chain disruptions increased lead times and costs for critical electronic components, affecting production schedules.
• Inflationary Pressures: Rising costs for raw materials, labor, and freight compressed profit margins, despite pricing optimization efforts.
• Competitive Landscape: Increased competition from established medical device companies and emerging home infusion players required greater sales and marketing investment.
• Regulatory Hurdles: Navigating complex and evolving global regulatory requirements, especially the European Medical Device Regulation (EU MDR), consumed significant resources.

Leadership & Strategy Changes: In Q2 2025, KORU appointed Dr. Emily Chen as its new Chief Medical Officer. Dr. Chen brings extensive experience in immunology and drug delivery systems, highlighting the company's commitment to clinical excellence and product innovation.

Leadership reaffirmed the company's overarching strategy, which focuses on three pillars:

1. Innovation: Accelerating the development and commercialization of the next-generation pump system.
2. Market Expansion: Increasing penetration in existing SCIg markets and exploring new therapeutic areas for subcutaneous delivery.
3. Operational Excellence: Driving efficiency and cost optimization across manufacturing and the supply chain.

Financial Health: Managing Liquidity and Debt

KORU's financial position remains stable, though tightly managed.

• Cash and Equivalents: KORU held $15.8 million in cash and cash equivalents as of December 31, 2025, down from $22.3 million at the end of 2024. This decrease reflects investments in R&D and working capital.
• Debt: The company had $20.0 million in outstanding debt under its credit facility, with a net debt-to-EBITDA ratio of approximately 2.5x. KORU remains in compliance with all financial covenants (conditions set by lenders).
• Liquidity: KORU believes its current cash and available $5.0 million credit facility will fund operations for at least the next 12 months. However, the company may consider future capital raises to accelerate growth initiatives.

Future Outlook: Focused on Innovation and Market Expansion

KORU is strategically positioned for future growth, with a clear roadmap focused on innovation and market expansion.

• New Product Development: KORU's primary focus is completing and commercializing its next-generation pump and consumable system. This system aims to offer enhanced features, improve patient experience, and reduce manufacturing costs, solidifying KORU's leadership in home infusion. The Q3 2026 FDA 510(k) submission is a critical milestone, with a potential market launch in late 2027.
• Market Expansion: KORU plans to expand its market share and product reach by targeting underserved patient populations and exploring new geographic markets, particularly in Europe and Asia. This expansion follows successful compliance with the EU MDR by December 2028.
• Increased Prescriptions: KORU aims to increase patient prescriptions for Subcutaneous Immunoglobulin (SCIg) therapies, often administered with its devices. The company will achieve this through continued collaboration with biopharmaceutical partners, clinical education, and direct-to-patient marketing. KORU targets a 5-7% annual increase in new SCIg patient starts using its devices over the next three years.
• Therapeutic Diversification: KORU is also exploring how its infusion technology can apply to other subcutaneous therapies beyond SCIg, potentially opening new revenue streams in areas like diabetes management or oncology support.

Competitive Position

KORU Medical Systems holds a strong niche in the home infusion market, especially for SCIg therapies. Its competitive advantages include:

• Specialized Expertise: Deep understanding of subcutaneous drug delivery and patient needs for chronic conditions.
• Established Brand: The FREEDOM Infusion System is a recognized and trusted brand among patients and clinicians.
• Product Portfolio: A comprehensive offering of pumps, infusion sets, and accessories tailored for home use. However, KORU faces competition from larger, diversified medical device companies and smaller, agile innovators. Maintaining leadership hinges on continuous innovation and strong clinical evidence.

Risk Factors

KORU highlights several risks that could impact its business, financial health, and stock price. Investors should understand these factors before making investment decisions:

• Business Operations & Products:

  • Innovation: KORU must constantly introduce new products and keep pace with technology. Failure to do so could harm its business.
  • Drug Supply Dependence: KORU's products rely on an adequate supply of drugs for administration. Interruptions in this supply could harm its business.
  • Market Size: The market for KORU's products may not meet expectations or could shrink.
  • Reliance on Key Distributors: A limited number of distributors account for a large portion of KORU's sales. Deteriorating relationships or changes in distributor purchasing patterns could negatively impact sales.
  • Single Suppliers: KORU sources many components and raw materials, especially for its consumable parts, from single suppliers. Issues with these suppliers (e.g., late delivery, unfavorable pricing) could disrupt operations.
  • Manufacturing Issues: Problems with KORU's own manufacturing or its contract manufacturers could harm its business.
  • Intense Competition: KORU operates in a highly competitive industry. Inability to keep pace with competitors could negatively affect its business.
  • Cybersecurity Threats: A cyberattack could disrupt KORU's systems, expose sensitive data, and harm its reputation and finances.
  • Intellectual Property Protection: Inability to protect its patents and trademarks, or accidental infringement on others' intellectual property, could damage KORU's competitiveness.
  • Talent Retention: KORU must attract and retain key employees to remain competitive.
  • Immigration Policies: Changes in immigration enforcement could affect KORU's workforce or suppliers.

• Industry & Regulatory Challenges:

  • FDA Approvals: Obtaining FDA approval (through 510(k) premarket notification or Premarket Approval (PMA)) for new products and improvements is crucial for growth. Delays or rejections would pose a significant problem.
  • Healthcare Policy & Cost Cutting: Changes in healthcare policies or cost-cutting efforts could pressure KORU's product pricing, limiting sales.
  • Product Quality: Product quality issues could lead to regulatory actions, loss of customer trust, and harm KORU's business.
  • Drug Efficacy: The effectiveness of some drugs used with KORU's devices may not be fully proven, or biopharma partners might cease developing these drugs, impacting KORU's related sales.
  • Market Acceptance of Partner Drugs: Even after approval, drugs used with KORU's devices require widespread acceptance by doctors, patients, and insurers for KORU to succeed.
  • Insurance Coverage: Inadequate insurance coverage for procedures using KORU's products would hinder sales and revenue.
  • Generic Competition: Brand-name injectable therapies will eventually face competition from cheaper generic versions, which could reduce their commercial appeal and impact KORU.
  • Complex Regulations: KORU faces complex and costly global laws and regulations. Non-compliance could lead to penalties and harm its business.
  • EU MDR Compliance: KORU must invest significantly to comply with new European Medical Device Regulations (EU MDR) by December 2028. Failure to comply would prevent the sale of its consumable products in the EU.
  • Reimbursement Laws: Failure to follow healthcare product reimbursement laws could lead to penalties and damage KORU's reputation.

• Economic & Financial Risks:

  • International Operations: KORU's international operations expose it to various risks.
  • Inflation: Rising inflation could force KORU to increase prices to maintain profit margins.
  • Currency Exchange: Foreign currency fluctuations could impact KORU's financial results.
  • Government Shutdowns: Government shutdowns could negatively affect KORU's business.
  • Economic Downturns: A weak global economy or issues in government-sponsored healthcare systems could harm KORU's operations.
  • Public Health Crises: Past public health crises, like COVID-19, have impacted KORU and could do so again.
  • Brexit: The UK's departure from the EU could impact KORU's business in that region.
  • Need for More Funding: KORU may need to raise additional capital in the future. Inability to do so could force it to slow down or cut back on product development or sales efforts.
  • Credit Facility Covenants: KORU must meet specific financial conditions under its loan agreements. Failure to do so could restrict further borrowing or trigger immediate repayment of existing loans.
  • Uninsured Assets: Some of KORU's cash at banks exceeds Federal Deposit Insurance Corporation (FDIC) insurance limits, meaning it could lose money if a bank fails.
  • Tax & Labor Law Changes: Changes in tax and labor laws could increase KORU's costs and reduce its profits.
  • Tariffs & Trade Policies: Trade policy changes could increase KORU's costs and reduce its profit margins.
  • Fluctuating Results: KORU's financial results and overall condition may vary significantly from period to period.
  • Asset Impairments: Significant drops in the value of KORU's long-term assets could negatively affect its operating results.

• Stock Ownership Risks:

  • Shareholder Conflicts: The interests of KORU's major shareholders may not always align with yours.
  • No Dividends: KORU does not currently plan to pay dividends on its common stock.
  • Stock Dilution: Future share issuances (e.g., through employee stock plans) could reduce your ownership percentage in KORU.
  • Stock Price Volatility: KORU's stock price has been, and may remain, volatile.
  • Nasdaq Delisting: Failure to meet Nasdaq's listing rules could lead to KORU's stock being delisted.
  • Smaller Reporting Company Status: As a smaller reporting company with fewer reporting requirements, KORU's stock may be less attractive to some investors.
  • Difficulty Selling Stock: Limited trading activity could make selling KORU shares difficult.

Market Trends & Regulatory Changes

The home infusion market continues to grow, fueled by an aging population, rising chronic disease rates, and a shift toward value-based care models that favor home treatment. Regulatory changes, such as the ongoing implementation of the EU MDR, present both challenges and opportunities for KORU to differentiate through compliance and product quality. The increasing adoption of digital health solutions and remote patient monitoring also offers avenues for KORU to integrate its devices into broader connected care ecosystems.